HOME >> BIOLOGY >> NEWS
Smelling for first time results from knowing abnormalities in congenital loss of smell

growth factors responsible for olfactory stem cell maturation and function. Without these growth factors, olfactory receptor cells can not maintain normal cell function. As he suspected, the nasal mucus from these patients was deficient in these important growth factors.

The studies also found a double whammy in these patients nasal mucus. Normal mucus contains not only growth factors to allow new olfactory receptor cells to function, it also contains death factors that kill the aging receptor cells (a normal process of programmed cell death, or apoptosis), making way for the new. The congenital smell loss patients had five to 10 times the concentration of these death factors as do people who can smell. That guaranteed that the high concentration of death factor would destroy any receptor cell growth that was able to take place.

After determining the family of enzymes to which the growth and death factors belong and defining the biochemical pathway responsible for these factors, Dr. Henkin was able to treat these patients with PDE inhibitors that increase the concentration of growth factors and inhibit the secretion o death factors in nasal mucus. The treatment has been successful in restoring smell function in some of these patients, with the higher the dose and longer the use having the greatest effect.


'"/>

Contact: Sylvia Wrobel
ebpress@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
30-Apr-2007


Page: 1 2

Related biology news :

1. Saudi Arabias KAUST names WHOI first research partner
2. Which came first, the moth or the cactus?
3. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
4. Seawater intrusion is the first cause of contamination of coastal aquifers
5. Camera-shy deer caught for first time
6. CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell
7. New joint replacement material developed at MGH put to first clinical use
8. Liverpool amongst first in UK to install unique DNA sequencing technology
9. A first-principles model of early evolution
10. Worlds first X-ray free electron laser is on course to completion
11. Scientists identify first gene linked to scoliosis

Post Your Comments:
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Appleā€™s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
(Date:4/16/2015)... Seattle, Washington (PRWEB) April 16, 2015 ... for Applied Cancer Science and Resolution Bioscience, Inc. ... agreement to co-develop a novel, blood-based, clinic ready, ... lung cancer (NSCLC). The collaboration is the first ... ALK, RET, and ROS1 fusions in blinded plasma ...
Breaking Biology Technology:Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
Cached News: